Related references
Note: Only part of the references are listed.Structural Basis of SARS-CoV-2-and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics
Hariharan Sivaraman et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 (2021)
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Philippe Colson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
Martin C. Michel et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The Science Underlying COVID-19 Implications for the Cardiovascular System
Peter P. Liu et al.
CIRCULATION (2020)
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors
Fan Zhenzhen et al.
EMBO MOLECULAR MEDICINE (2020)
The many faces of the anti-COVID immune response
Santosha A. Vardhana et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Cell entry mechanisms of SARS-CoV-2
Jian Shang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Cytokine release syndrome in severe COVID-19
John B. Moore et al.
SCIENCE (2020)
Rapid repurposing of drugs for COVID-19
R. Kiplin Guy et al.
SCIENCE (2020)
Estimating the burden of SARS-CoV-2 in France
Henrik Salje et al.
SCIENCE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
Why COVID-19 Silent Hypoxemia Is Baffling to Physicians
Martin J. Tobin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle
Clarisse Salgado-Benvindo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Discovering small-molecule therapeutics against SARS-CoV-2
Vaibhav Tiwari et al.
DRUG DISCOVERY TODAY (2020)
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
Serena Di Cosimo et al.
EUROPEAN JOURNAL OF CANCER (2020)
The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
Qing Ye et al.
JOURNAL OF INFECTION (2020)
Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
Siyu Xiu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
Chee Wah Tan et al.
NATURE BIOTECHNOLOGY (2020)
Candidate drugs against SARS-CoV-2 and COVID-19
Dwight L. McKee et al.
PHARMACOLOGICAL RESEARCH (2020)
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial
Daryoush Hamidi Alamdari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
How does SARS-CoV-2 cause COVID-19?
Nicholas J. Matheson et al.
SCIENCE (2020)
A single unified model for fitting simple to complex receptor response data
Peter Buchwald
SCIENTIFIC REPORTS (2020)
Methylene blue inhibits replication of SARS-CoV-2 in vitro
Mathieu Gendrot et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Acute respiratory distress syndrome from Covid-19: A perfect storm from free radicals? Proposal for a new treatment
Giulio Scigliano et al.
MEDICAL HYPOTHESES (2020)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40-CD154 Costimulatory Protein-Protein Interaction
Damir Bojadzic et al.
MOLECULES (2018)
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction
Jinshui Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge
Duncan E. Scott et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Thomas C. Baddeley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction
Yun Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Modulators of Protein-Protein Interactions
Lech-Gustav Milroy et al.
CHEMICAL REVIEWS (2014)
Plasma Treated with Methylene Blue and Light: Clinical Efficacy and Safety Profile
Miguel Lozano et al.
TRANSFUSION MEDICINE REVIEWS (2013)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor
Lakshmi Ganesan et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Lest we forget you - methylene blue ...
R. Heiner Schirmer et al.
NEUROBIOLOGY OF AGING (2011)
Rationalizing the chemical space of protein-protein interaction inhibitors
Olivier Sperandio et al.
DRUG DISCOVERY TODAY (2010)
Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods
Christelle Reynes et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Suramin inhibits the CD40-CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects
Emilio Margolies-Clark et al.
BIOCHEMICAL PHARMACOLOGY (2009)
High absolute bioavailability of methylene blue given as an aqueous oral formulation
Ingeborg Walter-Sack et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction
Emilio Margolles-Clark et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Protein therapeutics: A summary and pharmacological classification
Benjamin Leader et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods
Alexander Neugebauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Scaffolds for blocking protein-protein interactions
Stefan J. Hershberger et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Targeting protein-protein interactions by rational design: mimicry of protein surfaces
Steven Fletcher et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Development of small molecules designed to modulate protein-protein interactions
Ye Che et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2006)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Methylene blue improves the hepatopulmonary syndrome
P Schenk et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
